Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedLipoglycopeptideFDA-approved 2009 · VibativBoxed warning

Telavancin

A vancomycin derivative with a second way to kill bacteria

Telavancin is a lipoglycopeptide antibiotic made from vancomycin. It blocks bacterial cell-wall building and also damages the bacterial membrane. Approved as Vibativ in 2009, it is given once daily by infusion for complicated skin infections and, when other options are unsuitable, Staphylococcus aureus pneumonia.

Manufacturer's recommended dosing (FDA label): 10 mg/kg (CrCl >50 mL/min), Every 24 hours, over 60 minutes, Intravenous Details ↓

Overview

What is it?

Telavancin belongs to the lipoglycopeptides, vancomycin relatives with a fatty side chain, alongside dalbavancin and oritavancin. Like vancomycin it blocks the building of the bacterial cell wall, and its side chain also disrupts the bacterial membrane. It acts against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Its half-life is about 8 hours, so it is infused once a day.

In the ATLAS programme of 1,867 patients with complicated skin infections, success was 88% on telavancin and 87% on vancomycin, and cure in MRSA infections was 91% against 86%. In two pneumonia trials totalling 1,503 patients, cure rates were similar overall (58.9% against 59.5%), but mortality was higher with telavancin in patients with pre-existing kidney impairment. In patients with mixed Gram-positive and Gram-negative pneumonia, cure rates favoured vancomycin.

That finding produced a boxed warning for increased mortality in pneumonia patients with moderate or severe kidney impairment, alongside warnings for kidney toxicity and potential harm in pregnancy. The label reserves its pneumonia use for when alternatives are not suitable and cuts the dose as creatinine clearance falls: 7.5 mg/kg daily at 30 to 50 mL/min and 10 mg/kg every 48 hours below 30, with too little data below 10.

Kidney function shapes its use in practice too. Dialysis removes over a quarter of a dose when run soon after it, and a hospital that capped doses at 750 mg in obese patients saw fewer adverse effects without losing efficacy. In a small phase 2 trial in S. aureus bloodstream infection, cure rates matched standard therapy, but few patients were evaluable.

A population model pooling 1,205 people from 21 studies found clearance tracks kidney function, body weight, age and infection type, and modelling for obese patients with kidney impairment favoured a fixed 750 mg starting point over weight-based dosing. Adults with cystic fibrosis have been studied too, because their drug handling differs.

Off label, it has been used for bone infections, with high cure rates in a retrospective series of 32 patients. People who had a severe drug reaction (DRESS) to vancomycin may cross-react: in one immunology study two of fifteen such patients reacted to telavancin and teicoplanin, though none to dalbavancin.

88% vs 87%
Skin infection success vs vancomycin
ATLAS, 1,867 patients · PMID 18444791
10 mg/kg
Once daily over 60 minutes
Vibativ label 2.1
~8 h
Terminal half-life
Label 12.3
Science

Mechanism of Action

Telavancin is a lipoglycopeptide: it blocks bacterial cell-wall synthesis like vancomycin and also damages the bacterial membrane.

🧱

Cell-wall synthesis

Binds cell-wall precursors as vancomycin does, stopping Gram-positive bacteria from building peptidoglycan.

💥

Membrane disruption

Its fatty side chain also disrupts the bacterial membrane, a second route of killing.

🩺

Kidney-dependent

Clearance rises with creatinine clearance in pooled pharmacokinetic data; the label cuts the dose as kidney function falls (label 2.3).

Evidence

Published Research

The trials behind telavancin, from their PubMed abstracts.

Human2008

ATLAS: complicated skin infections

In 1,867 patients, clinical success was 88% on telavancin and 87% on vancomycin; among 579 patients with MRSA, cure was 91% against 86% and microbiological eradication 90% against 85%.

PMID: 18444791
Human2011

ATTAIN: hospital-acquired pneumonia

In 1,503 patients, cure rates were 58.9% on telavancin and 59.5% on vancomycin overall, higher with telavancin in monomicrobial S. aureus infection; mortality in one study was 21.5% against 16.6%.

PMID: 21148517
Human2005

FAST: phase 2 in skin infections

In 167 randomised patients with complicated skin and soft-tissue infections, success was similar to standard therapy; in the 48 with MRSA, cure was 82% on once-daily telavancin against 69% on standard therapy, and eradication 84% against 74%.

PMID: 15889357
Human2014

ASSURE: uncomplicated S. aureus bacteraemia

In a double-blind phase 2 trial of 60 patients, cure was 88% on telavancin and 89% on standard therapy among the 17 clinically evaluable; adverse events (90% against 72%) and significant creatinine rises were more common with telavancin.

PMID: 24884578
Human2018

Kidney function over time in ATTAIN

Among 1,503 pneumonia patients, creatinine-clearance declines were steady on telavancin (19.3% at day 4, 23.0% at end of therapy) but climbed on vancomycin (8.4% to 19.3%); vancomycin did significantly better at days 4 and 7, with no significant difference at the end.

PMID: 30003567
Human2021

Haemodialysis

In patients on haemodialysis, a session 3 hours after the dose removed about 28% of circulating telavancin and shortened its half-life to 13.1 hours, against 20.9 hours when dosed after dialysis.

PMID: 34613416
Human2022

A capped dose in obesity

At a community teaching hospital, capping the dose at 750 mg in obese patients was associated with equal efficacy and fewer adverse effects than standard 10 mg/kg dosing by total body weight. It was an observational comparison.

PMID: 34662182
Human2019

Osteomyelitis in practice

In 32 retrospective cases of osteomyelitis, over half MRSA, 87.5% were cured or improved at the end of telavancin and 94.6% three months later. Osteomyelitis is not a labelled use.

PMID: 31256939
Human2021

Cross-reactivity after vancomycin DRESS

Of 15 patients with HLA-A*32:01-linked vancomycin DRESS, none reacted to dalbavancin ex vivo, but two cross-reacted to teicoplanin and telavancin.

PMID: 32439433
Human2025

Pooled pharmacokinetics, 1,205 people

A population model from 21 studies, including healthy volunteers and patients with skin infections, pneumonia and bacteraemia, found clearance linked to creatinine clearance, with body weight, age and infection type explaining variation between people.

PMID: 40503947
Human2019

Cystic fibrosis exacerbations

In 18 adults with cystic fibrosis admitted for exacerbations and given 7.5 or 10 mg/kg daily, clearance rose with creatinine clearance and volume with body weight; simulations were used to choose doses for this population.

PMID: 31685468
Human2021

Modelling obesity with kidney impairment

A physiologically based model predicted exposure rising 1.07- to 1.57-fold from mild impairment to end-stage kidney disease in obese patients with pneumonia, and suggested a fixed 750 mg-based dose over dosing by total body weight. It is a simulation, not a trial.

PMID: 33447912
Review2017

Telavancin's place

A review of telavancin as a semi-synthetic lipoglycopeptide with a dual mechanism against resistant Gram-positive bacteria, summarising its clinical trials and its kidney-related safety limits.

PMID: 28634536
Dosing

Dosing Data

Vibativ is infused intravenously over 60 minutes once a day, at 10 mg/kg with normal kidney function, for 7 to 14 days in skin infections and 7 to 21 days in pneumonia.

Hospital antibiotic with a boxed warning: higher mortality in pneumonia patients with moderate or severe kidney impairment, kidney toxicity and potential fetal harm.
ProtocolDoseFrequencyDurationRoute
Label: complicated skin and skin structure infections Approved labelVibativ (telavancin) for injection US prescribing information (DailyMed set 5359b759, effective December 19, 2025)10 mg/kg (CrCl >50 mL/min)Every 24 hours, over 60 minutes7-14 daysIntravenous
Label: hospital-acquired and ventilator-associated pneumonia Approved labelVibativ (telavancin) for injection US prescribing information (DailyMed set 5359b759, effective December 19, 2025)10 mg/kg (CrCl >50 mL/min)Every 24 hours, over 60 minutes7-21 daysIntravenous
Label: kidney impairment Approved labelVibativ (telavancin) for injection US prescribing information (DailyMed set 5359b759, effective December 19, 2025)7.5 mg/kg (CrCl 30-50) or 10 mg/kg (CrCl 10-<30)Every 24 hours or every 48 hours respectivelyAs aboveIntravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Weight-based, kidney-adjusted
Telavancin is dosed in mg/kg with creatinine clearance by Cockcroft-Gault using ideal body weight, and prepared by the hospital pharmacy.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Vibativ (telavancin hydrochloride injection): VIBATIV is supplied in single-dose vials containing 750 mg telavancin as a sterile, lyophilized powder. Single-dose vials containing 750 mg telavancin. Forms the label lists: single-dose vials.

Source: Vibativ (telavancin hydrochloride injection) label, section 3 (DailyMed version 6, effective December 19, 2025).

Mixing a vial: a worked example

The approved product Vibativ (telavancin hydrochloride injection) is a powder that is mixed before use, with the liquid and volume its label names. Follow the label, not a general example. Its label says: “Reconstitute the contents of a VIBATIV 750 mg vial with 45 mL of 5% Dextrose Injection, USP; Sterile Water for Injection, USP; or 0.9% Sodium Chloride Injection, USP.”

Source: Vibativ (telavancin hydrochloride injection) label, sections 2 and 3 (DailyMed version 6, effective December 19, 2025).

Storage before and after mixing

Before mixing or first use: “Store original packages at refrigerated temperatures of 2°C to 8°C (35°F to 46°F).”

After mixing or first use: “Studies have shown that the reconstituted solution in the vial should be used within 12 hours when stored at room temperature or within 7 days under refrigeration at 2 to 8°C (36 to 46°F).” “The diluted (dosing) solution in the infusion bag can also be stored at -30 to -10°C (-22 to 14°F) for up to 32 days.”

Source: Vibativ (telavancin hydrochloride injection) label, sections 16 and 2 (DailyMed version 6, effective December 19, 2025).

How it is taken

As the approved label gives it: Intravenous (Every 24 hours, over 60 minutes; Label: complicated skin and skin structure infections).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of terminal half-life about 8 hours (8.0 single dose, 8.1 multiple doses). After about five half-lives almost none is left.

How long the doses were given: Label: complicated skin and skin structure infections: 7-14 days; Label: hospital-acquired and ventilator-associated pneumonia: 7-21 days; Label: kidney impairment: As above.

When effects appear: unknown; no source on this page gives a time to effect for Telavancin. Results reported in the studies are under Published Research.

Source: half-life: Vibativ prescribing information, section 12.3 (DailyMed set 5359b759, effective December 19, 2025); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Adverse events comparable to vancomycin in the pneumonia trials; Higher mortality in patients with pre-existing kidney impairment. Full list and cautions ↓

Boxed warning on the label: Increased mortality in habp/vabp patients with pre-existing moderate or severe renal impairment, nephrotoxicity, potential adverse developmental outcomes.

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Telavancin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: Vibativ (telavancin hydrochloride injection) label, boxed warning and section 5 (DailyMed version 6, effective December 19, 2025); the Side Effects section below (“From the studies above”).

Interactions

  • coagulation tests (PT, INR, aPTT, ACT): telavancin binds the phospholipid reagents and falsely raises results shortly after infusion
  • urine protein tests: interferes with dipstick and dye-method urine protein assays; microalbumin assays are unaffected

Every peptide's record, with its source: the interaction matrix.

Source: Cumberland/Theravance. VIBATIV (telavancin) US prescribing information, section 7. DailyMed version of December 19, 2025, read October 3, 2026.

Checking what you bought

Unknown: no published independent test of Telavancin products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Vibativ on September 11, 2009 (NDA 022110) for complicated skin and skin structure infections). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Adverse events comparable to vancomycin in the pneumonia trials
● Higher mortality in patients with pre-existing kidney impairment

Contraindications & Cautions

Warnings from the Vibativ label (DailyMed, effective December 19, 2025).

● Boxed warning: increased mortality in pneumonia patients with moderate or severe kidney impairment, nephrotoxicity, potential harm to the fetus
● Decreased response in skin infections with kidney impairment
● Interference with blood clotting tests
● Hypersensitivity, infusion reactions and C. difficile diarrhoea
Questions

Frequently Asked Questions

?Is telavancin a peptide?

Yes, in the broad sense: like vancomycin it is a glycopeptide, a cross-linked peptide core carrying sugars, here with an added fatty side chain.

?Why does telavancin have a boxed warning?

In pneumonia trials, patients with pre-existing moderate or severe kidney impairment had higher mortality on telavancin than on vancomycin. The label also warns of kidney toxicity and potential harm in pregnancy.

?How does it compare with vancomycin?

In large trials it matched vancomycin for skin infections and pneumonia overall, with somewhat higher cure rates against MRSA in skin infections.

?How is telavancin given?

By intravenous infusion over 60 minutes once every 24 hours, for 7 to 14 days for skin infections and 7 to 21 days for pneumonia, with the dose adjusted for kidney function, according to the label.

?Is telavancin safe in pregnancy?

The label's boxed warning says it may cause fetal harm, based on adverse developmental outcomes in three animal species at clinically relevant doses, and advises verifying pregnancy status before starting and effective contraception during treatment.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): VIBATIV, NDA 022110 (September 11, 2009) and NDA 022407 (June 21, 2013). Read October 3, 2026.
  2. [fda-pi] FDA. Vibativ (telavancin) US prescribing information (DailyMed set 5359b759-db7c-4672-9e8a-59c93869bd91, version 6, effective December 19, 2025). Read October 3, 2026.
  3. [clinical-trial] Stryjewski ME, et al. "Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms." Clin Infect Dis, 2008;46(11):1683-93. PMID: 18444791.
  4. [clinical-trial] Rubinstein E, et al. "Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens." Clin Infect Dis, 2011;52(1):31-40. PMID: 21148517.
  5. [pubmed] Das B, et al. "Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens." Ther Adv Infect Dis, 2017;4(2):49-73. PMID: 28634536.
  6. [clinical-trial] Stryjewski ME, et al. "Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria." Clin Infect Dis, 2005;40(11):1601-7. PMID: 15889357.
  7. [clinical-trial] Stryjewski ME, et al. "A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study." BMC Infect Dis, 2014;14:289. PMID: 24884578.
  8. [pubmed] Nogid B, et al. "Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials." Pharmacotherapy, 2018;38(10):990-998. PMID: 30003567.
  9. [pubmed] Gharibian KN, et al. "Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis." J Antimicrob Chemother, 2021;77(1):174-180. PMID: 34613416.
  10. [pubmed] Diggs FJ, et al. "Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital." Antimicrob Agents Chemother, 2022;66(1):e0160321. PMID: 34662182.
  11. [pubmed] Saravolatz LD, et al. "Real-world use of telavancin in the treatment of osteomyelitis." Diagn Microbiol Infect Dis, 2019;95(2):185-190. PMID: 31256939.
  12. [pubmed] Nakkam N, et al. "Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype." J Allergy Clin Immunol, 2021;147(1):403-405. PMID: 32439433.
  13. [fda-pi] Vibativ (telavancin) for injection US prescribing information (DailyMed set 5359b759, version 6, effective December 19, 2025), sections 2.1-2.3; read through openFDA October 6, 2026.
  14. [pubmed] Van Wart SA, et al. "Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections." Antimicrob Agents Chemother, 2025;69(7):e0138224. PMID: 40503947.
  15. [pubmed] Kidd JM, et al. "Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation." Antimicrob Agents Chemother, 2019;64(1). PMID: 31685468.
  16. [pubmed] Wu W, et al. "Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment." Eur J Clin Pharmacol, 2021;77(7):989-998. PMID: 33447912.

Sources & Citations

Studies were read from their PubMed abstracts; the Vibativ label from DailyMed (set 5359b759, effective December 19, 2025) through openFDA, read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03